Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H19F2N3O3 |
Molecular Weight | 387.38 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C(=O)C1=CC(O[C@H]2CCOC3=CC(F)=CC(F)=C23)=C4NC(C)=NC4=C1
InChI
InChIKey=CLIQCDHNPDMGSL-HNNXBMFYSA-N
InChI=1S/C20H19F2N3O3/c1-10-23-14-6-11(20(26)25(2)3)7-17(19(14)24-10)28-15-4-5-27-16-9-12(21)8-13(22)18(15)16/h6-9,15H,4-5H2,1-3H3,(H,23,24)/t15-/m0/s1
Tegoprazan is an oral, selective, reversible inhibitor of gastric H+/K+-ATPase that has a fast onset of action and can control gastric pH for a prolonged period. It was developed for the treatment of acid-related gastrointestinal diseases such as gastroesophageal reflux disease (GERD) and peptic ulcers. Tegoprazan has received a license from the Ministry of Food and Drug Safety in Korea for the treatment of gastroesophageal reflux disease and erosive oesophagitis. In addition, the drug is involved in phase III clinical trial to evaluate the triple therapy (tegoprazan, amoxicillin, and clarithromycin) in H. Pylori positive patients. This trial is on the stage of recruiting the patients.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/30843245
Once daily administration of tegoprazan 50 or 100 mg showed non-inferior efficacy in healing EE and tolerability to that of esomeprazole 40 mg.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29723
Created by
admin on Fri Dec 15 19:44:32 GMT 2023 , Edited by admin on Fri Dec 15 19:44:32 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
300000020956
Created by
admin on Fri Dec 15 19:44:32 GMT 2023 , Edited by admin on Fri Dec 15 19:44:32 GMT 2023
|
PRIMARY | |||
|
10169
Created by
admin on Fri Dec 15 19:44:32 GMT 2023 , Edited by admin on Fri Dec 15 19:44:32 GMT 2023
|
PRIMARY | |||
|
23582846
Created by
admin on Fri Dec 15 19:44:32 GMT 2023 , Edited by admin on Fri Dec 15 19:44:32 GMT 2023
|
PRIMARY | |||
|
942195-55-3
Created by
admin on Fri Dec 15 19:44:32 GMT 2023 , Edited by admin on Fri Dec 15 19:44:32 GMT 2023
|
PRIMARY | |||
|
C152542
Created by
admin on Fri Dec 15 19:44:32 GMT 2023 , Edited by admin on Fri Dec 15 19:44:32 GMT 2023
|
PRIMARY | |||
|
DB16690
Created by
admin on Fri Dec 15 19:44:32 GMT 2023 , Edited by admin on Fri Dec 15 19:44:32 GMT 2023
|
PRIMARY | |||
|
W017G7IF4S
Created by
admin on Fri Dec 15 19:44:32 GMT 2023 , Edited by admin on Fri Dec 15 19:44:32 GMT 2023
|
PRIMARY |
ACTIVE MOIETY